Generex Biotechnology Announces that its Subsidiar
Post# of 36537
(Total Views: 335)
Posted On: 05/16/2019 9:45:53 AM
Generex Biotechnology Announces that its Subsidiary Olaregen Therapeutix Launches Excellagen at The Symposium on Advanced Wound Care (SAWC) in San Antonio, TX
9:00 AM ET, 05/16/2019 - GlobeNewswire
MIRAMAR, Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that its Subsidiary, Olaregen Therapeutix has officially launched Excellagen Wound Conforming Matrix. Generex and Olaregen launched Excellagen during its debut at The Symposium on Advanced Wound Care (SAWC) in San Antonio, TX. SAWC is the premier interdisciplinary wound care program in the United States. Its annual gathering hosted wound care clinicians and renowned educators from the United States and around the world and garnered over 2000 attendees. This 5-day event brings wound care professionals together and features 80+ sessions across 6 dynamic tracks, covering practical approaches to wound care and the very latest developments in wound healing research.
On Tuesday, May 7, 2019, SmartTRAK presented the latest Trends, Opportunities and Innovations in Advanced Wound Care at SAWC Spring. Susan Paquette, VP & General Manager and Lennart Stadler, Senior Analyst, both of SmartTRAK, were the featured speakers. Ms. Paquette focused on the Biologic segment and spoke to three new innovative products introduced to the Cellular Tissue Product Market. One of the three featured technologies was Excellagen, Olaregen's Formulated Fibrillar Collagen (2.6%) Wound Conforming Matrix. Excellagen was chosen among this group based on its clinical data from the Randomized Controlled, Multiple Centered Clinical Study where Excellagen closed Diabetic Foot Ulcers in 1.6 applications, potentially reducing the overall cost of treating hard to heal wounds. With CMS evaluating the current fee for service model and potentially moving more towards more of an episodic payment, Excellagen's positive clinical results could benefit clinicians and payers in any future payment model changes.
Olaregen is poised to become a significant force in regenerative medicine, as we are providing comprehensive training to over 75 biotech sales professionals for specialty hospital sales across the US, strategically concentrating our efforts in key metropolitan areas. We have had unprecedented interest from new, potential partners proceeding and following SAWC, and we are building our sales team and growing our distribution channels to serve the wound care market. “It is truly fulfilling to hear how excited the sales team is to sell our new regenerative medicine product, and how eager physicians are to evaluate Excellagen in practice. So many of our team and customers enthusiastically say to me that Excellagen will have a positive impact on patients and caregivers, providing an exciting treatment option for providers that treat hard to manage wounds.” Scott Emmens, Sr. VP of Sales and Business Development.
CEO Anthony J. Dolisi stated, “Olaregen recognizes the significance of sound partnerships and solid execution and has worked diligently to secure the core channels of a successful commercial product. On May 14th , Olaregen secured a 3pl and distribution agreement with McKesson, and our sales team, in conjunction with our distribution network, spans the United States for a national footprint. These commercialization efforts will focus on sales to hospital surgical suites, acute care centers, and hospital operating rooms. Additionally, Olaregen has secured sales support for our Service-Disabled Veteran-Owned Small Business (SDVOSB) partners to best service and support the VA and Department of Defense. We look forward to an exciting 2019 for Excellagen.
9:00 AM ET, 05/16/2019 - GlobeNewswire
MIRAMAR, Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that its Subsidiary, Olaregen Therapeutix has officially launched Excellagen Wound Conforming Matrix. Generex and Olaregen launched Excellagen during its debut at The Symposium on Advanced Wound Care (SAWC) in San Antonio, TX. SAWC is the premier interdisciplinary wound care program in the United States. Its annual gathering hosted wound care clinicians and renowned educators from the United States and around the world and garnered over 2000 attendees. This 5-day event brings wound care professionals together and features 80+ sessions across 6 dynamic tracks, covering practical approaches to wound care and the very latest developments in wound healing research.
On Tuesday, May 7, 2019, SmartTRAK presented the latest Trends, Opportunities and Innovations in Advanced Wound Care at SAWC Spring. Susan Paquette, VP & General Manager and Lennart Stadler, Senior Analyst, both of SmartTRAK, were the featured speakers. Ms. Paquette focused on the Biologic segment and spoke to three new innovative products introduced to the Cellular Tissue Product Market. One of the three featured technologies was Excellagen, Olaregen's Formulated Fibrillar Collagen (2.6%) Wound Conforming Matrix. Excellagen was chosen among this group based on its clinical data from the Randomized Controlled, Multiple Centered Clinical Study where Excellagen closed Diabetic Foot Ulcers in 1.6 applications, potentially reducing the overall cost of treating hard to heal wounds. With CMS evaluating the current fee for service model and potentially moving more towards more of an episodic payment, Excellagen's positive clinical results could benefit clinicians and payers in any future payment model changes.
Olaregen is poised to become a significant force in regenerative medicine, as we are providing comprehensive training to over 75 biotech sales professionals for specialty hospital sales across the US, strategically concentrating our efforts in key metropolitan areas. We have had unprecedented interest from new, potential partners proceeding and following SAWC, and we are building our sales team and growing our distribution channels to serve the wound care market. “It is truly fulfilling to hear how excited the sales team is to sell our new regenerative medicine product, and how eager physicians are to evaluate Excellagen in practice. So many of our team and customers enthusiastically say to me that Excellagen will have a positive impact on patients and caregivers, providing an exciting treatment option for providers that treat hard to manage wounds.” Scott Emmens, Sr. VP of Sales and Business Development.
CEO Anthony J. Dolisi stated, “Olaregen recognizes the significance of sound partnerships and solid execution and has worked diligently to secure the core channels of a successful commercial product. On May 14th , Olaregen secured a 3pl and distribution agreement with McKesson, and our sales team, in conjunction with our distribution network, spans the United States for a national footprint. These commercialization efforts will focus on sales to hospital surgical suites, acute care centers, and hospital operating rooms. Additionally, Olaregen has secured sales support for our Service-Disabled Veteran-Owned Small Business (SDVOSB) partners to best service and support the VA and Department of Defense. We look forward to an exciting 2019 for Excellagen.
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼